InspireMD

InspireMD Ltd.is a medical device company focusing on the development and commercialization of its proprietary stent platform technology – MGuard™. MGuard is designed to be the only complete solution for high risk Acute Coronary Syndrome patients, – A market that consists of over 2 million patients /year.

The Market

InspireMD addresses approximately 50% of a $6 billion coronary market:

patients with acute coronary syndromes (“ACS”), Acute Myocardial Infarction (“AMI”) and Saphenous Vein Graft interventions (“SVG”).

During and post stenting procedure 12% to 19% of the patients face major adverse cardiac events (“MACE”) with no satisfactory solution.

The Company plans to establish the safety and efficacy of MGuard™ via a series of randomized trials, to become the industry standard for treatment of acute coronary syndromes.  The Company plans to have four marketed and approved products in the U.S., Europe, Japan and other markets.

MGuard: The “Choice for Life” device

The MGuard™ Stent system, is based on a micron level knit net that wraps a standard balloon expandable stent. The net blocks embolic showers, providing protection during and post stenting procedure. The net also diffuses stent pressure and reduces injury to the vessel, thereby lowering the risk of restenosis and protecting the artery wall from stent injury and damage.

The MGuard™ net’s fiber width is smaller than a typical endothelial cell; therefore transparent to the endothelization process.  This design helps reduce major adverse events.

MGuard’s combination of ease-of-use with significant patients’ benefits makes it an ideal alternative to any solution on the market.

Superior clinical results

In clinical trials conducted across Europe MGuard™ has demonstrated a considerable advantage over any other existing solution both in terms of safety and efficacy in its vast and lucrative market niche.

For the first time, patients will benefit from a cost-effective solution, greater clinical efficacy and a higher safety profile than any other existing technology.

InspireMD intends to apply its technology for additional vascular interventions, specifically carotid, cerebral and peripheral.

Intellectual property

InspireMD has filed 5 patent families that cover all aspects of the technology: minimal fiber width, macro structure, drug delivery, snow shoe effect, and anchoring.

InspireMD Ltd.
3 Menorat Hamaor st.
Tel Aviv, Israel, 67448

T: +972.3.691.7691
F: +972.3.691.7692
info@inspire-md.com
www.inspire-md.com